A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630

Status	RECRUITING
Phase	Phase 3
Sponsor	argenx
Enrollment	160 participants

Key Eligibility Criteria

Inclusion (5)

- Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
- Has residual disability and active disease
- Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)
- Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP

Exclusion (5)

- Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- Sensory CIDP (including sensory-predominant CIDP)
- Polyneuropathy of other causes
- Clinical diagnosis of systemic lupus erythematosus (SLE)
- Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation

Locations (19 total)

Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States
Medstar Health Research Institute, Washington D.C., District of Columbia, United States
Gables Neurology, Miami, Florida, United States
... and 16 more locations